Aavogen Gene Therapy Platform Muscle Wasting Disease Heart Failure

Aavogen is a gene therapy platform company developing muscle-specific rAAV therapeutics for muscle wasting and heart failure. AVGN7 targets inclusion body myositis (lead), heart failure (HFrEF/HFpEF), and sarcopenic obesity, while AVGND addresses Duchenne muscular dystrophy. The company's proprietary AAVMYO2 capsid and CK8e promoter enable muscle-specific delivery to prevent off-target toxicities.